Combined with flexibility, creativity, and innovation our scientific approach enables fast, efficient, and high quality ex*****on of complex clinical development programs. Our skilled and loyal networks of investigators all around the world allow us to offer superior recruitment in therapeutic area’s such as cardiology, diabetes, CNS and infectious diseases. Our partners include leading pharmaceut
ical, biotech, medical device, and food companies, as well as academic investigators and research consortia. We focus on clinical trials likely to have a major impact on the practice of medicine and patient outcomes. This demanding research requires more than a ‘one-size-fits-all’ approach, and our fusion of scientific and operational expertise enables delivery of results efficiently, on time and budget. Julius Clinical employs internationally recognized academic leaders who are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and influence, combined with personal links with peers around the world, provides a truly global reach and reputation. Julius Clinical has completed over 50 investigator-initiated and industry-sponsored trials, enrolling over 130.000 patients across 30 countries worldwide, involving innovative pharmaceuticals in a broad range of therapeutic areas, including infectious diseases, cardiovascular and metabolic
diseases, and central nervous system (CNS) diseases. Through our global networks we can quickly select the most appropriate and
highest-performing sites to take part in a trial and ensure that investigators are inspired
and motivated. We currently have a cardiology network of about 1000 sites, about 500 general internal medicine and 2000 general practitioners. Julius Clinical was
incorporated in 2008 and is affiliated with the Julius Center for Health Sciences and Primary Care at the University Medical Center Utrecht, the Netherlands. We are dedicated to operational and academic excellence. We are Julius Clinical. Please contact us for more information.
